Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. (not Lifemd, Inc.) on May 29, 2018, reporting a material definitive agreement entered into on the same date. The Company, incorporated in Delaware, is an emerging growth company.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued and sold senior secured convertible notes with an aggregate original principal amount of $550,000.
- Interest Rate: Notes bear interest compounded annually at 12%.
- Maturity: The notes mature on the first anniversary of the Closing Date (May 29, 2019).
- Warrants: Investors received warrants to purchase up to 2,391,305 shares of common stock at an exercise price of $0.28 per share, exercisable for five years.
- Conversion Price: The initial conversion price for the notes is $0.23 per share, subject to adjustments including a potential reduction to 80% of the VWAP if specific market conditions are met.
- Liquidity and Collateral: The notes are secured by a lien on substantially all of the Company's assets. A subsidiary, Immudyne PR, LLC, provided a guaranty for the obligations.
Material Changes and Covenants
The filing details significant new financial obligations and restrictive covenants:
- Lock-Up Period: The Company is restricted from issuing new securities for one year (until May 29, 2019), subject to exempted issuances.
- Variable Rate Transactions: The Company is prohibited from entering into variable rate transactions while the notes are outstanding.
- Future Financing Rights: Investors have a one-year right to participate pro rata in future financing transactions.
- Executive Pledge: The CEO, Justin Schreiber, pledged shares held by his wholly-owned entities (JOJ Holdings, LLC and JLS Ventures, LLC) as additional security.
- Registration Rights: The Company must file a registration statement within 30 days to register shares issuable upon conversion or warrant exercise.
Outlook, Risks, and Contingencies
The transaction introduces specific risks and contingencies:
- Dilution Risk: The conversion price includes a "ratchet" provision that reduces the price if the Company issues stock at a lower effective price, potentially increasing dilution.
- Default Provisions: The notes contain standard events of default. Upon default, the collateral agent may exercise remedies against substantially all Company assets.
- Unregistered Sale: The securities were sold under Section 4(a)(2) and/or Regulation D exemptions, meaning they were not registered under the Securities Act of 1933 at the time of issuance.
Investor Verification Checklist
- Verify the current status of the registration statement required to be filed within 30 days of the closing.
- Confirm the Company's ability to service the 12% interest and principal repayment due in May 2019.
- Review the impact of the 4.99% beneficial ownership limitation on the conversion of notes.
- Assess the extent of assets pledged under the Security Agreement and the potential impact on future operations.
- Monitor compliance with the one-year lock-up on new securities issuances.